NCT06255769 Diagnosis of Myocardial Ischemia With MCG Using SPECT as a Reference Standard
| NCT ID | NCT06255769 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Qilu Hospital of Shandong University |
| Condition | Chest Pain |
| Study Type | OBSERVATIONAL |
| Enrollment | 228 participants |
| Start Date | 2024-02-12 |
| Primary Completion | 2024-10-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 228 participants in total. It began in 2024-02-12 with a primary completion date of 2024-10-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This is a prospective clinical study aiming to investigate the efficacy of Magnetocardiography (MCG) in detecting myocardial ischemia in patients of a suspected non-ST-elevation-acute coronary syndrome (NSTE-ACS) by using Single photon emission computed tomography (SPECT) as the gold standard for determining the presence and severity of myocardial ischemia.
Eligibility Criteria
Inclusion Criteria: * Age 18 years or older; * Patients with symptoms of myocardial ischemia such as angina pectoris, who have CAG showing \<70% stenosis at the most severe site or CTA showing non-severe stenosis * Signed informed consent. Exclusion Criteria: * Patients with absolute or relative contraindications to SPECT-loaded myocardial perfusion, including acute myocardial infarction within 48 hours, significant left main coronary artery stenosis, bronchial asthma, and adenosine injection allergy; * Patients with Non-ischemic dilated cardiomyopathy, or hypertrophic cardiomyopathy, or moderate or severe valvular disease; * Patients with Hemodynamic instability (systolic blood pressure\<90 mmHg, or who requires vasoactive drugs), or patients with tachyarrhythmia, Ⅱdegree atrioventricular block and above that have not returned to normal; * Patients who have severe renal abnormality with eGFR \<30 ml/min, or patients who are on dialysis; * Patients with malignant tumors with predicted survival of less than 1 year; * Pregnant or breastfeeding women; * Patients who are unable to enter the MCG device, who are unable to perform MCG examination due to interference from metal implants or other reasons, or who are deemed by the investigators to be unsuitable for enrollment.
Contact & Investigator
Yuguo Chen, Professor
PRINCIPAL INVESTIGATOR
Qliu Hospital of Shandong University
Frequently Asked Questions
Who can join the NCT06255769 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Chest Pain. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06255769 currently recruiting?
Yes, NCT06255769 is actively recruiting participants. Contact the research team at jiaojiaopang@126.com for enrollment information.
Where is the NCT06255769 trial being conducted?
This trial is being conducted at Jinan, China.
Who is sponsoring the NCT06255769 clinical trial?
NCT06255769 is sponsored by Qilu Hospital of Shandong University. The principal investigator is Yuguo Chen, Professor at Qliu Hospital of Shandong University. The trial plans to enroll 228 participants.